Sugi Predict

Sugi Predict / Compounds / SCHEMBL220097

SCHEMBL220097

SCHEMBL220097

O=C1CN(Cc2ccccc2)CCN1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 2/20 0.62
▸ GRM5 P41594 1/20 0.50
▸ KMT2A Q03164 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ HIF1A Q16665 1/20 0.49
▸ SLC2A1 P11166 1/20 0.48
▸ SLC6A5 Q9Y345 1/20 0.48
▸ GAA P10253 1/20 0.47
▸ DDB1 Q16531 1/20 0.46
▸ CRBN Q96SW2 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ LTA4H P09960 1/20 0.45
▸ GSK3A P49840 1/20 0.45
▸ GSK3B P49841 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5704266 0.90 SIGMAR1 (0.54) SIGMAR1KMT2AALDH1A1MEN1CYP2C9
SCHEMBL7546347 0.89 APP (0.52) SIGMAR1GRM5KMT2AALDH1A1MEN1
SCHEMBL28499086 0.87 SIGMAR1 (0.51) SIGMAR1KMT2AALDH1A1MEN1CYP2C9
SCHEMBL8024414 0.86 SIGMAR1 (0.58) SIGMAR1KMT2AALDH1A1MEN1CYP2C9
SCHEMBL2904306 0.86 SIGMAR1 (0.62) SIGMAR1KMT2AALDH1A1MEN1CYP2C9
SCHEMBL4751222 0.85 SMN1; SMN2 (0.58) SIGMAR1KMT2AALDH1A1MEN1SLC2A1
SCHEMBL4748942 0.83 ALDH1A1 (0.61) SIGMAR1KMT2AALDH1A1MEN1ATM
SCHEMBL1427302 0.83 ALDH1A1 (0.47) SIGMAR1KMT2AALDH1A1MEN1ATM
SCHEMBL17468364 0.83 CXCR4 (0.55) GRM5KMT2AALDH1A1MEN1GAA
SCHEMBL153020 0.83 SIGMAR1 (0.53) SIGMAR1KMT2AMEN1TSHRACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326721-A1 SSAO INHIBITORS AND USE THEREOF ECCOGENE INC (US) 2025-10-23 — — US disclosed
CN-118742543-A Dihydro isoquinoline compound and medical application thereof 中国科学院上海药物研究所 2024-10-01 — — CN disclosed
CN-114901649-B SSAO inhibitors and uses thereof 诚益生物(美国)公司 2024-07-23 — — CN disclosed
US-11964942-B2 SSAO inhibitors and use thereof ECCOGENE (SHANGHAI) CO., LTD. (CN) 2024-04-23 — — US disclosed
WO-2023222850-A1 AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES ASTRAZENECA AB (SE) 2023-11-23 — — WO disclosed
US-11807646-B2 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2023-11-07 — — US disclosed
WO-2023174383-A1 DIHYDROISOQUINOLINE COMPOUND AND MEDICAL USE THEREOF 中国科学院上海药物研究所 2023-09-21 — — WO disclosed
US-20230026801-A1 SSAO INHIBITORS AND USE THEREOF ECCOGENE INC. 2023-01-26 — — US disclosed
EP-3746432-B1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LTD (GB) 2022-12-14 — — EP disclosed
US-11472769-B2 SSAO inhibitors and use thereof ECCOGENE (SHANGHAI) CO., LTD. (CN) 2022-10-18 — — US disclosed
US-6974869-B2 Piperizinones as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-12-13 — — US disclosed
US-20050261311-A1 Piperizinones as modulators of chemokine receptor activity DELUCCA GEORGE V 2005-11-24 — — US disclosed
US-20030144277-A1 Piperizinones as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-07-31 — — US disclosed
WO-2003024401-A2 PIPERIZINONES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2003-03-27 — — WO disclosed
EP-0107423-B1 NOVEL CHROMANS AND CHROMENES BEECHAM GROUP PLC (GB) 1986-07-23 — — EP disclosed
US-4593098-A Piperazinone and piperazine polypeptides THE UPJOHN COMPANY (US) 1986-06-03 — — US disclosed
US-4534897-A Piperazinone, piperazine, 1,4-diazepin-2-one and 1,4-diazepine intermediate compounds THE UPJOHN COMPANY (US) 1985-08-13 — — US disclosed
US-4496565-A HYPOTENSIVE AGENTS BEECHAM GROUP P.L.C. (GB) 1985-01-29 — — US disclosed
EP-0107423-A1 Novel chromans and chromenes BEECHAM GROUP PLC (GB) 1984-05-02 — — EP disclosed
US-4251438-A ANALGESICS, PSYCHOTHERAPEUTIC AGENTS THE UPJOHN COMPANY (US) 1981-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964942-B2 SSAO inhibitors and use thereof SSB, HAO1, SORD SIGMAR1 1966/4885GRM5 4402/4885KMT2A 4745/4885
US-20030144277-A1 Piperizinones as modulators of chemokine receptor activity CCR3, CCR1, CCR5 SIGMAR1 1165/4885GRM5 272/4885KMT2A 4077/4885
US-20250326721-A1 SSAO INHIBITORS AND USE THEREOF SSB, HAO1, SORD SIGMAR1 1966/4885GRM5 4402/4885KMT2A 4745/4885
US-20230026801-A1 SSAO INHIBITORS AND USE THEREOF SSB, HAO1, SORD SIGMAR1 1966/4885GRM5 4402/4885KMT2A 4745/4885
US-20050261311-A1 Piperizinones as modulators of chemokine receptor activity CCR3, CCR1, CCR5 SIGMAR1 1457/4885GRM5 265/4885KMT2A 4085/4885
US-11472769-B2 SSAO inhibitors and use thereof SSB, HAO1, SORD SIGMAR1 1966/4885GRM5 4402/4885KMT2A 4745/4885
US-11807646-B2 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) USP19, USP16, USP18 SIGMAR1 4079/4885GRM5 3481/4885KMT2A 1484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.